Acadia Pharma (ACAD) Tops Q2 EPS by 12c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $28.42 -1.76%
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, PMCB, PLCE, More
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.18, $0.12 better than the analyst estimate of $0.06. Revenue for the quarter came in at $307.96 million versus the consensus estimate of $296.02 million.
FY 2026 Outlook:-
Revenue between $1.24 to $1.30 billion vs consensus $1.24 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
- Ciena beats estimates on strong AI-driven demand, shares rise
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
